Melodiol Global Health Limited

ME1

AU0000282840

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:45 2024-04-26 am EDT			5-day change	1st Jan Change
0.003 ^AUD	-25.00%		-33.33%	-92.50%

Apr. 16	Melodiol Global's Revenue Surges 79% in Q1	MT
Apr. 09	Melodiol Global Health Subsidiary Health House Australia to Launch Medicinal Cannabis Clinic	MT

Creso Pharma Limited Reports Earnings Results for the Half Year Ended June 30, 2021

August 31, 2021 at 03:37 am EDT

Creso Pharma Limited announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was AUD 3.031 million compared to AUD 1.453 million a year ago. Net loss was AUD 18.966 million compared to AUD 17.406 million a year ago. Basic loss per share from continuing operations was AUD 0.0185 compared to AUD 0.0797 a year ago.

Latest news about Melodiol Global Health Limited

Melodiol Global's Revenue Surges 79% in Q1	Apr. 15	MT
Melodiol Global Health Subsidiary Health House Australia to Launch Medicinal Cannabis Clinic	Apr. 08	MT
Melodiol Global Health Posts 148% Increase in FY 2023 Revenue to AU$21.6 Million	Mar. 26	MT
Melodiol Global Health Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Melodiol Unit to Add Cannabis Products Across Six Canadian Provinces	Feb. 13	MT
Melodial's Unit Logs AU$1 Million Revenues in January	Feb. 07	MT
Melodiol Global Health Limited Announces Resignation of Erlyn Dawson as Joint Company Secretary	Dec. 21	CI
Melodiol Global Health Limited Reports Unaudited Revenue Results for the Nine Months of 2023	Nov. 12	CI
Melodiol Global's Canadian Arm Mernova Posts Record Sales for October	Nov. 02	MT
Melodiol Global Health Achieves 80% Remission Rate from Phase Two Hallucinogenic Trial	23-10-11	MT
Melodial's Canadian Arm Mernova Logs Record Sales in Q3	23-10-10	MT
Melodiol Global Health Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Panacea Life Sciences Holdings, Inc. entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million.	23-08-01	CI
Melodiol Logs Strong Start to Q3 with AU$1.6 Million in Revenue and Confirmed Purchase Orders	23-07-20	MT
Melodiol Global Health Limited Announces Revenue Results for Third Quarter of 2023	23-07-18	CI
Melodiol Global Health Triples Q2 Net Sales	23-07-13	MT
Creso Pharma Changes Name to Melodiol Global Health	23-06-12	MT
Creso Pharma Signs Deal to Import Psychedelic Medication into Australia	23-06-09	MT
Creso Pharma's Subsidiary Hires Consultant to Support Licensing Process in Australia, Europe	23-06-04	MT
Creso Pharma Raises AU$2.5 Million Via Share Issue	23-05-19	MT
ASX Halts Creso Pharma's Trading Amid Pending Announcement	23-05-18	MT
Health House International to be Removed from Australian Bourse's Official List	23-05-17	MT
Creso Pharma Limited completed the acquisition of Health House International Limited.	23-05-15	CI
Creso Pharma Expands Pet Care Range to Asia with Distribution Deals	23-05-15	MT
Creso Pharma Validates Efficacy of Psychedelic Drug in Phase 2 PTSD Trial	23-05-05	MT

Chart Melodiol Global Health Limited

Duration

Period

More charts

Company Profile

Melodiol Global Health Limited, formerly Creso Pharma Limited, is an Australia-based cannabis company. The Company is engaged in developing cannabis and hemp-derived therapeutic-grade nutraceuticals and medical cannabis products with a range of applications in both human and animal health. Its cannabidiol (CBD) plant-based nutraceutical products are non-psychoactive, as they only contain trace amounts of tetrahydrocannabinol (THC). Its product is offered under various brands, including Green Goo, Southern Butter, Good Goo, Ritual, impactive and cannaQIX, among others. It cultivates and harvests cannabis plants through its subsidiary, Mernova Medicinal Inc. and supplies cannabis retail products throughout Canada. Through its wholly owned, Canada-based psychedelics subsidiary, Halucenex Life Sciences Inc., it is also focused on the development of synthetic and botanical psilocybin treatments for treatment-resistant post-traumatic stress disorder, and other mental health conditions.

Sector

Pharmaceuticals

Calendar

2024-05-30 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MELODIOL GLOBAL HEALTH LIMITED	-92.50%	1.75M
NOVO NORDISK A/S	+25.20%	556B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+7.95%	296B
ASTRAZENECA PLC	+13.51%	233B
NOVARTIS AG	+5.63%	201B
ROCHE HOLDING AG	-10.14%	193B
PFIZER, INC.	-12.26%	143B
AMGEN INC.	-6.47%	144B